Table 1.
Cancer | CRT levels* | Clinical outcomes | Reference |
---|---|---|---|
Oral | Increased | — | [43] |
Esophagus | Increased | ↓ survival (poor prognosis) | [44] |
Breast | Increased | ↑ metastasis, ↑ invasion, ↓ survival | [45–47] |
Pancreas | Increased | ↑ lymph node metastasis, ↑ UICC stage, ↓ survival | [48] |
Gastric | Increased | ↑ lymph node metastasis, ↑ invasion, ↑ microvessel density, ↓ survival | [49] |
Colon | Increased | — | [50] |
Bladder | Increased | ↑ urinary CRT, ↑ histological grade, ↑ pathological T stage | [51–53] |
Prostate | Increased | — | [54] |
Vagina | Increased | — | [55] |
#Ovarian | Increased | Better response to chemotherapy | [55, 56] |
#Neuroblastoma | Increased | ↑ differentiation, ↑ survival | [57] |
↑: increased; ↓: decreased.
*CRT levels in tumor tissue except ovarian carcinoma in effusion fluids.
#Higher levels of CRT seem to correlate with good prognosis for the diseases.